Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK); First commercial launch anticipated in ...